Abstract:Purpose: In this study, we designed a new linear 6-Hydrazinonicotinamide (HYNIC)-conjugated peptide (HYNIC-KRWrNM) (M-6) and labeled with technetium-99m for gamma imaging of glioblastoma as a αvβ3-positive tumor. We evaluated tumor targeting ability of this radio-peptide and compared with previous 99mTc-labeled HYNIC-conjugated RGD analogue peptides. Procedures: One new linear peptide (HYNIC-KRWrNM) (M-6) was designed and labeled with technetium-99m in the presence of 2-[[1,3-dihydroxy-2-(hydroxymethyl) propan-2-yl] amino] acetic acid (Tricine)/Ethylenediamine-N,N'-diacetic acid (EDDA) as co-ligand system. Then, this 99mTc-labeled peptide ([99mTc]Tc-M-7) was evaluated for in vitro stability in saline and serum, specific binding assay, internalization, and binding affinity (Kd). In addition, we performed biodistribution study and planar imaging on nude mice bearing U87-MG xenograft as a αvβ3-positive tumor. Results: The radiochemical yield of [99mTc]Tc-M-7 was obtained ˃95%. This 99mTc-labeled peptide remained stable and intact in saline solution after 24 h incubation. In addition, metabolic stability of this 99mTc-labeled peptide was obtained ˃60% after 4 h incubation in serum. The Kd value for [99mTc]Tc-M-7 was obtained 5.2 ± 1.0 nM. Based on biodistribution results in nude mice bearing U87-MG xenograft, tumor/muscle activity ratio was 6.22 and decreased to 1.89 in blocking group at the same time point (4 h p.i.). The blocking experiment results also indicated that tumor uptake and kidney uptake were αvβ3-mediated. In comparison with previous HYNIC-conjugated RGD analogue peptides, kidneys had the highest uptake of this 99mTc-labeled peptide (52.29 ± 11.48 at 1.5 h p.i. and 27.04 ± 0.66%ID/g at 4 h p.i.). Finally, similar to previous 99mTc-labeled HYNIC-conjugated RGD analogue peptides, [99mTc]Tc-M-7 showed acceptable tumor uptake after 4 h post-injection (based on ROI technique, target-to-background activity ratio = 3.80). Conclusions: This small linear 99mTc-labeled peptide, with high affinity to αvβ3 integrin, desirable water solubility, and cost efficient, demonstrates a potent tumor targeting ability as well as previous HYNIC-conjugated RGD analogue peptides. Hence, [99mTc]Tc-M-7 can be of service to as a new candidate for early detection of αvβ3-positive tumors.

Tumor Locating Property of ~(99)Tc~m-Mavgg-glucose

Biodistribution and Pharmacokinetics of 99tcm Labeled Carbohydrated Peptides in Mice Bearing Tumors

The preparation and biological evaluation of 99mTc-MAG3-glucose

99Tcmn-Dgdtc,a New Glucose Metabolic Agent,the Pharmacokinetics and Imaging Results

Synthesis and Biodistribution of A New 99Mtc-Oxo Complex with Deoxyglucose Dithiocarbamate for Tumor Imaging

Investigations of (99M)tc-Labeled Glucarate As a SPECT Radiotracer for Non-Small Cell Lung Cancer (NSCLC) and Potential Tumor Uptake Mechanism.

Biodistribution and Imaging of 99m Tc-MAVGG-adenine in Tumor Bearing Mice

A pre-targeting strategy for imaging glucose metabolism using technetium-99m labelled dibenzocyclooctyne derivative.

99 Tcm-labeled Glucose Metabolism Imaging Agents Based on in Vivo Copper-free Click Chemistry

Novel 99mTc-Labeled Mannose Derivative as a Highly Promising Single Photon Emission Computed Tomography Probe for Tumor Imaging

Radio-Labeling and Micro-Pet Study of Cu-64 Labeled D-Glucose for Tumor Imaging

<sup>99m</sup>Tc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin α<sub>v</sub>β<sub>3</sub>Expression

99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression

99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression.

Synthesis and Evaluation of (68)Ga-Labeled DOTA-2-deoxy-D-glucosamine As a Potential Radiotracer in Μpet Imaging.

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

Synthesis and single photon emission computed tomography imaging evaluation with 99mTc-labeled bevacizumab in colorectal cancer xenografts

Synthesis and Biodistribution of 99Tcm-MAG2-Ade as A Tumor Imaging Agent

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

Imaging of 99Tcm-Labeled New Cyclic RGDfK Dimer in Nude Mice Bearing U87MG Human Glioma Xenografts

PET Imaging of 18F-(2 S,4 R)4-Fluoroglutamine Accumulation in Breast Cancer: From Xenografts to Patients